Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
AMS vs ARAY vs NVCR vs GKOS vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
Medical - Instruments & Supplies
AMS vs ARAY vs NVCR vs GKOS vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $13M | $35M | $1.92B | $7.85B | $161.07B |
| Revenue (TTM) | $29M | $429M | $674M | $551M | $10.58B |
| Net Income (TTM) | $-2M | $-46M | $-173M | $-189M | $2.98B |
| Gross Margin | 25.0% | 26.8% | 75.2% | 78.1% | 66.3% |
| Operating Margin | -12.3% | -5.1% | -27.2% | -15.6% | 30.5% |
| Forward P/E | 6.1x | — | — | — | 43.8x |
| Total Debt | $23M | $176M | $290M | $140M | $303M |
| Cash & Equiv. | $11M | $57M | $103M | $91M | $3.37B |
AMS vs ARAY vs NVCR vs GKOS vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| American Shared Hos… (AMS) | 100 | 109.2 | +9.2% |
| Accuray Incorporated (ARAY) | 100 | 14.0 | -86.0% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Glaukos Corporation (GKOS) | 100 | 344.2 | +244.2% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMS vs ARAY vs NVCR vs GKOS vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMS is the #2 pick in this set and the best alternative if growth exposure and valuation efficiency is your priority.
- Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
- PEG 0.93 vs ISRG's 2.01
- 32.9% revenue growth vs ARAY's 2.7%
- Lower P/E (6.1x vs 43.8x), PEG 0.93 vs 2.01
ARAY lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
GKOS ranks third and is worth considering specifically for momentum.
- +52.0% vs ARAY's -78.4%
ISRG carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.02
- 5.5% 10Y total return vs GKOS's 457.1%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- Beta 1.02, current ratio 4.87x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs ARAY's 2.7% | |
| Value | Lower P/E (6.1x vs 43.8x), PEG 0.93 vs 2.01 | |
| Quality / Margins | 28.2% margin vs GKOS's -34.3% | |
| Stability / Safety | Beta 1.02 vs ARAY's 2.42, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +52.0% vs ARAY's -78.4% | |
| Efficiency (ROA) | 14.8% ROA vs GKOS's -20.1%, ROIC 15.0% vs -9.2% |
AMS vs ARAY vs NVCR vs GKOS vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AMS vs ARAY vs NVCR vs GKOS vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 2 of 6 categories
GKOS leads 1 • AMS leads 0 • ARAY leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 359.7x AMS's $29M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $429M | $674M | $551M | $10.6B |
| EBITDAEarnings before interest/tax | $2M | -$15M | -$165M | -$40M | $3.8B |
| Net IncomeAfter-tax profit | -$2M | -$46M | -$173M | -$189M | $3.0B |
| Free Cash FlowCash after capex | -$10M | -$28M | -$48M | -$18M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +25.0% | +26.8% | +75.2% | +78.1% | +66.3% |
| Operating MarginEBIT ÷ Revenue | -12.3% | -5.1% | -27.2% | -15.6% | +30.5% |
| Net MarginNet income ÷ Revenue | -7.6% | -10.8% | -25.7% | -34.3% | +28.2% |
| FCF MarginFCF ÷ Revenue | -34.7% | -6.5% | -7.1% | -3.4% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | -7.4% | +12.3% | +41.2% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.7% | -6.1% | -100.0% | -6.3% | +18.8% |
Valuation Metrics
Evenly matched — AMS and ARAY each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 6.1x trailing earnings, AMS trades at a 89% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), AMS offers better value at 0.93x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $13M | $35M | $1.9B | $7.9B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $25M | $154M | $2.1B | $7.9B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | 6.09x | -18.91x | -13.80x | -40.90x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | — | — | 2.65x |
| EV / EBITDAEnterprise value multiple | 7.51x | 10.99x | — | — | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 0.46x | 0.08x | 2.92x | 15.47x | 16.00x |
| Price / BookPrice ÷ Book value/share | 0.45x | 0.37x | 5.51x | 11.69x | 9.17x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 64.67x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-77 for ARAY. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs GKOS's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.9% | -77.5% | -50.8% | -26.5% | +16.9% |
| ROA (TTM)Return on assets | -3.8% | -10.1% | -16.5% | -20.1% | +14.8% |
| ROICReturn on invested capital | -5.8% | +3.0% | -16.4% | -9.2% | +15.0% |
| ROCEReturn on capital employed | -6.4% | +2.8% | -28.9% | -10.3% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.77x | 2.17x | 0.85x | 0.21x | 0.02x |
| Net DebtTotal debt minus cash | $12M | $119M | $187M | $49M | -$3.1B |
| Cash & Equiv.Liquid assets | $11M | $57M | $103M | $91M | $3.4B |
| Total DebtShort + long-term debt | $23M | $176M | $290M | $140M | $303M |
| Interest CoverageEBIT ÷ Interest expense | -1.35x | -1.86x | -96.80x | -18.69x | — |
Total Returns (Dividends Reinvested)
GKOS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $606 for ARAY. Over the past 12 months, GKOS leads with a +52.0% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs ARAY's -56.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.3% | -65.5% | +28.3% | +21.2% | -19.3% |
| 1-Year ReturnPast 12 months | -27.4% | -78.4% | +1.1% | +52.0% | -15.4% |
| 3-Year ReturnCumulative with dividends | -28.0% | -91.8% | -75.7% | +128.7% | +49.6% |
| 5-Year ReturnCumulative with dividends | -41.1% | -93.9% | -91.3% | +61.5% | +58.7% |
| 10-Year ReturnCumulative with dividends | -4.7% | -94.5% | +30.3% | +457.1% | +554.2% |
| CAGR (3Y)Annualised 3-year return | -10.4% | -56.6% | -37.6% | +31.7% | +14.4% |
Risk & Volatility
Evenly matched — AMS and GKOS each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GKOS currently trades 91.4% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 2.42x | 2.20x | 1.20x | 1.02x |
| 52-Week HighHighest price in past year | $3.11 | $2.10 | $20.06 | $146.75 | $603.88 |
| 52-Week LowLowest price in past year | $1.25 | $0.28 | $9.82 | $73.16 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +64.6% | +14.0% | +83.9% | +91.4% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 58.4 | 69.8 | 63.0 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 138K | 1.4M | 1.5M | 678K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NVCR as "Buy", GKOS as "Buy", ISRG as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 9.3% for GKOS (target: $147).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $33.50 | $146.67 | $622.60 |
| # AnalystsCovering analysts | — | — | 15 | 24 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | +1.4% |
ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GKOS leads in 1 (Total Returns). 2 tied.
AMS vs ARAY vs NVCR vs GKOS vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AMS or ARAY or NVCR or GKOS or ISRG a better buy right now?
For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.
9% revenue growth year-over-year, versus 2. 7% for Accuray Incorporated (ARAY). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMS or ARAY or NVCR or GKOS or ISRG?
On trailing P/E, American Shared Hospital Services (AMS) is the cheapest at 6.
1x versus Intuitive Surgical, Inc. at 57. 6x.
03Which is the better long-term investment — AMS or ARAY or NVCR or GKOS or ISRG?
Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.
5%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMS or ARAY or NVCR or GKOS or ISRG?
By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.
02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately -15516% more volatile than AMS relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — AMS or ARAY or NVCR or GKOS or ISRG?
By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.
9% versus 2. 7% for Accuray Incorporated (ARAY). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMS or ARAY or NVCR or GKOS or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMS or ARAY or NVCR or GKOS or ISRG more undervalued right now?
Analyst consensus price targets imply the most upside for NVCR: 99.
0% to $33. 50.
08Which pays a better dividend — AMS or ARAY or NVCR or GKOS or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AMS or ARAY or NVCR or GKOS or ISRG better for a retirement portfolio?
For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
02)). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -4. 7%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMS and ARAY and NVCR and GKOS and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMS is a small-cap high-growth stock; ARAY is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.